Yoga Pranayama Adjuvant to Treat Burden COVID-19 (YOCO)
Primary Purpose
Coronavirus Infection, Cytokine Storm, Mental Disorder
Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
morning Yoga-based breathing support
pre_lunch Yoga-based breathing support
pre_dinner Yoga-based breathing support
Sponsored by
About this trial
This is an interventional supportive care trial for Coronavirus Infection focused on measuring COVID-19, CYTOKINE STORM, MEDICAL YOGA PRANAYAMA, VAGUS NERVE STIMOLATION, MENTAL DISORDER
Eligibility Criteria
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the trial;
- Male or Female, aged 18 years or above;
- Diagnosed COVID-19's infection;
- Informed consent;
- Having been diagnosed in the last 1 week;
- In the Investigator's opinion, is able and willing to comply with all trial requirements;
- Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial;
- Patients who continue to be followed at home.
Exclusion Criteria:
The participant may not enter the trial if ANY of the following apply:
- No informed consent;
- Participant is not willing and able to give informed consent for participation in the trial;
- Female participant who is pregnant, lactating or planning pregnancy during the course of the trial;
- Hospitalization patients;
- Having a serious cognitive impairment;
- Having serious hearing and vision problems;
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial;
- Participants who have participated in another research trial involving an investigational product in the past 12 weeks.
Sites / Locations
- Ambulatorio Telemedicina Giardino St Lucia
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Yoga-based breathing support
Arm Description
Three daily yoga pranayama breathing cycles within existing home-care provision of Covid19's patients (protocols shared dated 27 March 2020 by Italian Society of Infectious and Tropical Diseases - Italian General Practitioners Physician - Italian Society of General Medicine, Italy)
Outcomes
Primary Outcome Measures
Mortality
COVID-19's Patients mortality all cause: incidence proportion.
Mortality-suicide
COVID-19's Patients suicide: incidence proportion.
Secondary Outcome Measures
Incidence of hospitalization for respiratory failure of COVID-19's Patients-
In-hospital COVID-19's Patients oxygen invasive ventilation or high flow oxygen devices :incidence proportion of Brescia COVID-19 respiratory Severity Scale Index (Levels 0-3 worse outcome) cutoff Level ≥ 2 -
Incidence of al home professional psychiatric-psychological interventions for mental disorder.
Homecare interventions for anxiety and depression requiring drugs treatment: incidence proportion.
Incidence of mental disorder: Beck Depression Inventory-Second Edition (BDI-II).
Scoring system for depression and anxiety requiring drugs treatment: incidence proportion of BDI-II aggregate components score 0- 63 ( worse outcome) , cutoff > 29.
Incidence od spleep disorder:Pittsburgh Sleep Quality Index (PSQI).
Scoring system for sleep disorders requiring drugs treatment: incidence proportion of aggregate PSQI score 0-21 (worse outcome) , cutoff > 8.
Full Information
NCT ID
NCT04413747
First Posted
May 29, 2020
Last Updated
August 5, 2020
Sponsor
Health Ricerca e Sviluppo S.R.L.
Collaborators
Swami Vivekananda Yoga Anusandhana Samsthana, Bangaluru , India, Yoga Experience Association,Cervia (Ra), Italy, EJTN GEIE, Brussellese, Belgium, Casa di Riposo e Ambulatorio Giardino St Lucia, Massa Lomabarda (Ra) Italy, Halnet Srl, Faenza (Ra), Italy
1. Study Identification
Unique Protocol Identification Number
NCT04413747
Brief Title
Yoga Pranayama Adjuvant to Treat Burden COVID-19
Acronym
YOCO
Official Title
Yoga- Based Breathing for Vagus Nerve Stimulation as Home-care Adjuvant Treatment Against Burden COVID-19
Study Type
Interventional
2. Study Status
Record Verification Date
August 2020
Overall Recruitment Status
Unknown status
Study Start Date
August 15, 2020 (Anticipated)
Primary Completion Date
June 1, 2021 (Anticipated)
Study Completion Date
September 30, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Health Ricerca e Sviluppo S.R.L.
Collaborators
Swami Vivekananda Yoga Anusandhana Samsthana, Bangaluru , India, Yoga Experience Association,Cervia (Ra), Italy, EJTN GEIE, Brussellese, Belgium, Casa di Riposo e Ambulatorio Giardino St Lucia, Massa Lomabarda (Ra) Italy, Halnet Srl, Faenza (Ra), Italy
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
COronaVIrus Disease or Severe Acute Respiratory Syndrome -CoV-2 or COVID-19, mortality occurs mainly from immunological behavior or by suicide after healing . In both cases, the causal link is coronavirus within the host response. The rationale of use of deep yoga breathing as adjuvant treatment to COVID-19 disease , is linked to the mechanical action to stimulate the vagus nerve through scalene and sternocleidomastoid muscles function of which the continuity of action bring to modulate upto suppress, the inflammatory reflex and pro-inflammatory cytokines overproduction and contextual lowering of the sympathetic stress response as a first cause of sleep and late mental disorders which can increase the annual suicide rate. An easily breathing medical Yoga protocol has been developed to test a cost-effective care provision, training, contact tracing and mass efficacy testing.
Detailed Description
COronaVIrus Disease or Severe Acute Respiratory Syndrome -CoV-2 or COVID-19, pandemic threatens patients, societies and healthcare systems around the world. Morbidity and lethality have a direct link with the early vicious circles triggered by an acute microcirculation endotheliopathy, a correlated coagulopathy, up to late hypoxic damage of multi organ tissue The host immunity determines the progress of the disease , its lethality and the need of care intensity. The clinical course of the infection consist of three stage of which only the third -which intervenes in a low incidence of patients - need of hospitalization for severe hyperinflammatory syndrome including acute respiratory failure, while first and the second or moderate pulmonary involvement, might manage and monitoring within a homecare program during quarantine. Actually, the rough mortality in Italy is - at the current date - 7.6 % with an expected death of 0.004 of the whole population. The late lethality - still little known - from COVID-19 is to be correlated with mental disorders from stress response emerging from the first three COVID-19's stages and which result in a significant increase in suicides that is estimated at 30% more than expected of 7.4 deaths for 100,000 residents. This estimate can be considered as stage 4 of the disease or post COVID-19 mortality. In this scenario, mortality of COVID-19 is by intensity response of "the host " and in the meantime, a cutoff for homecare, hospitalization and time-related stress disease. Lines of evidence reports that direct-indirect stimulation of vagus nerve bring to the modulating of pro-inflammatory cytokines with effective systemic anti-inflammatory effect and has shown antidepressant effects in chronic treatment resistant depression. Because the vagus nerve is linked to brain regions important in anxiety regulation (locus coeruleus, orbitofrontal cortex, insula, hippocampus and amygdala), this pathway is involved in perceiving various somatic and cognitive symptoms that characterize anxiety and mental disorder disorders. On the basis of all these reasoning we plan to introduce a medical based-yoga deep breathing for activation of vagus nerve by scalene and sternocleidomastoid muscles function during breathing, as an adjuvant of care of the 1-2 and 4 stages of the COVID-19 disease to counteract the cumulative incidence of mortality and better outcome. Medical yoga protocol has been developed and designed to test a cost-effective care provision, training, contact tracing and mass efficacy testing.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronavirus Infection, Cytokine Storm, Mental Disorder
Keywords
COVID-19, CYTOKINE STORM, MEDICAL YOGA PRANAYAMA, VAGUS NERVE STIMOLATION, MENTAL DISORDER
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Prospective cohort study based on clinical assessment. Model- based adjusted outcome via hierarchical comparison of control curves using COVID19 national epidemic data with cyber layer algorithm of population
Masking
None (Open Label)
Masking Description
identifier number (ID) without any refer to clinical assessment or to patients
Allocation
N/A
Enrollment
1000 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Yoga-based breathing support
Arm Type
Experimental
Arm Description
Three daily yoga pranayama breathing cycles within existing home-care provision of Covid19's patients (protocols shared dated 27 March 2020 by Italian Society of Infectious and Tropical Diseases - Italian General Practitioners Physician - Italian Society of General Medicine, Italy)
Intervention Type
Behavioral
Intervention Name(s)
morning Yoga-based breathing support
Other Intervention Name(s)
First procedure
Intervention Description
Low and deep inspiration and phonetic syllable OM laryngeal vibration ( OM technique) as expiratory exercises, sitting in easy pose. The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Bhramari pranayama n° of 5 RAc.
Intervention Type
Behavioral
Intervention Name(s)
pre_lunch Yoga-based breathing support
Other Intervention Name(s)
Second procedure
Intervention Description
Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Surya Bheda pranayama n° of 5 RAc.
Intervention Type
Behavioral
Intervention Name(s)
pre_dinner Yoga-based breathing support
Other Intervention Name(s)
Third procedure
Intervention Description
Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Nadi Shodhana pranayama n° of 5 RAc.
Primary Outcome Measure Information:
Title
Mortality
Description
COVID-19's Patients mortality all cause: incidence proportion.
Time Frame
12 months.
Title
Mortality-suicide
Description
COVID-19's Patients suicide: incidence proportion.
Time Frame
12 months.
Secondary Outcome Measure Information:
Title
Incidence of hospitalization for respiratory failure of COVID-19's Patients-
Description
In-hospital COVID-19's Patients oxygen invasive ventilation or high flow oxygen devices :incidence proportion of Brescia COVID-19 respiratory Severity Scale Index (Levels 0-3 worse outcome) cutoff Level ≥ 2 -
Time Frame
1 months.
Title
Incidence of al home professional psychiatric-psychological interventions for mental disorder.
Description
Homecare interventions for anxiety and depression requiring drugs treatment: incidence proportion.
Time Frame
12 months.
Title
Incidence of mental disorder: Beck Depression Inventory-Second Edition (BDI-II).
Description
Scoring system for depression and anxiety requiring drugs treatment: incidence proportion of BDI-II aggregate components score 0- 63 ( worse outcome) , cutoff > 29.
Time Frame
12 months.
Title
Incidence od spleep disorder:Pittsburgh Sleep Quality Index (PSQI).
Description
Scoring system for sleep disorders requiring drugs treatment: incidence proportion of aggregate PSQI score 0-21 (worse outcome) , cutoff > 8.
Time Frame
12 months.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participant is willing and able to give informed consent for participation in the trial;
Male or Female, aged 18 years or above;
Diagnosed COVID-19's infection;
Informed consent;
Having been diagnosed in the last 1 week;
In the Investigator's opinion, is able and willing to comply with all trial requirements;
Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial;
Patients who continue to be followed at home.
Exclusion Criteria:
The participant may not enter the trial if ANY of the following apply:
No informed consent;
Participant is not willing and able to give informed consent for participation in the trial;
Female participant who is pregnant, lactating or planning pregnancy during the course of the trial;
Hospitalization patients;
Having a serious cognitive impairment;
Having serious hearing and vision problems;
Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial;
Participants who have participated in another research trial involving an investigational product in the past 12 weeks.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Giorgio Noera, MD, PhD
Phone
+393358294727
Email
presidenza@healthricercaesviluppo.it
First Name & Middle Initial & Last Name or Official Title & Degree
Boris Bazzani, ERYT
Phone
+393384841931
Email
amministrazione@fbiteam.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nagarathna Raghuram, MD
Organizational Affiliation
Vivekananda Yoga Anusandhana Samsthana, Bengaluru, India
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
HR Nagendra., Eng
Organizational Affiliation
Vivekananda Yoga Anusandhana Samsthana, Bengaluru, India
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Maria Donatella Barbagallo, MD
Organizational Affiliation
Yoga Experience Association,Cervia (Ra), Italy
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Enrico Ricci, MD
Organizational Affiliation
Yoga Experience Association,Cervia (Ra), Italy
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Morena Gaddoni, MD
Organizational Affiliation
Casa di Riposo Giardino St Lucia, Massa Lombarda (Ra) Italy
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Maria Luisa Vitobello
Organizational Affiliation
EJTN GEIE, Brussellese, Belgium
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Luca Ghetti, Eng.
Organizational Affiliation
Halnet Srl
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Fabio Zucchetta, MD
Organizational Affiliation
Casa di Riposo Giardino St Lucia, Massa Lombarda (Ra) Italy
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ambulatorio Telemedicina Giardino St Lucia
City
Massa Lombarda
State/Province
Ravenna
ZIP/Postal Code
48024
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Morena Gaddoni
Phone
+39054581871
Email
direzione@giardinostlucia.it
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
The datasets generated during and/or analysed during the current study will be available upon request within a web_ client structure
IPD Sharing Time Frame
18 months
IPD Sharing Access Criteria
ID (nikname ) and password
IPD Sharing URL
https://ifc.cnr.it
Citations:
PubMed Identifier
32151325
Citation
Wenham C, Smith J, Morgan R; Gender and COVID-19 Working Group. COVID-19: the gendered impacts of the outbreak. Lancet. 2020 Mar 14;395(10227):846-848. doi: 10.1016/S0140-6736(20)30526-2. Epub 2020 Mar 6. No abstract available.
Results Reference
background
PubMed Identifier
28179016
Citation
Johansson PI, Stensballe J, Ostrowski SR. Shock induced endotheliopathy (SHINE) in acute critical illness - a unifying pathophysiologic mechanism. Crit Care. 2017 Feb 9;21(1):25. doi: 10.1186/s13054-017-1605-5. Erratum In: Crit Care. 2017 Jul 13;21(1):187.
Results Reference
background
PubMed Identifier
10839541
Citation
Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000 May 25;405(6785):458-62. doi: 10.1038/35013070.
Results Reference
background
PubMed Identifier
27382171
Citation
Koopman FA, Chavan SS, Miljko S, Grazio S, Sokolovic S, Schuurman PR, Mehta AD, Levine YA, Faltys M, Zitnik R, Tracey KJ, Tak PP. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8284-9. doi: 10.1073/pnas.1605635113. Epub 2016 Jul 5.
Results Reference
background
PubMed Identifier
20674737
Citation
Thayer JF, Sternberg EM. Neural aspects of immunomodulation: focus on the vagus nerve. Brain Behav Immun. 2010 Nov;24(8):1223-8. doi: 10.1016/j.bbi.2010.07.247. Epub 2010 Jul 30.
Results Reference
background
PubMed Identifier
30766497
Citation
Lv H, Zhao YH, Chen JG, Wang DY, Chen H. Vagus Nerve Stimulation for Depression: A Systematic Review. Front Psychol. 2019 Jan 31;10:64. doi: 10.3389/fpsyg.2019.00064. eCollection 2019.
Results Reference
background
PubMed Identifier
21103178
Citation
O'Reardon JP, Cristancho P, Peshek AD. Vagus Nerve Stimulation (VNS) and Treatment of Depression: To the Brainstem and Beyond. Psychiatry (Edgmont). 2006 May;3(5):54-63.
Results Reference
background
PubMed Identifier
32410757
Citation
Jordana J, Trivino-Salazar JC. Where are the ECDC and the EU-wide responses in the COVID-19 pandemic? Lancet. 2020 May 23;395(10237):1611-1612. doi: 10.1016/S0140-6736(20)31132-6. Epub 2020 May 13. No abstract available.
Results Reference
background
PubMed Identifier
32315758
Citation
Zhu S, Wu Y, Zhu CY, Hong WC, Yu ZX, Chen ZK, Chen ZL, Jiang DG, Wang YG. The immediate mental health impacts of the COVID-19 pandemic among people with or without quarantine managements. Brain Behav Immun. 2020 Jul;87:56-58. doi: 10.1016/j.bbi.2020.04.045. Epub 2020 Apr 18.
Results Reference
background
Available IPD and Supporting Information:
Available IPD/Information Type
Study Protocol
Available IPD/Information URL
http://giardinostlucia.it
Available IPD/Information Identifier
guest_1
Available IPD/Information Type
Informed Consent Form
Available IPD/Information URL
http://giardinostlucia.it
Available IPD/Information Identifier
guest_2
Available IPD/Information Type
Individual Participant Data Set
Available IPD/Information URL
http://giardinostlucia.it
Available IPD/Information Identifier
guest_3
Learn more about this trial
Yoga Pranayama Adjuvant to Treat Burden COVID-19
We'll reach out to this number within 24 hrs